

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 71711

**Title:** Treatment of gastric hepatoid adenocarcinoma with pembrolizumab and bevacizumab combination chemotherapy: A case report

**Provenance and peer review:** Unsolicited manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 06135401

**Position:** Peer Reviewer

**Academic degree:** MD, MSc

**Professional title:** Assistant Professor, Senior Postdoctoral Fellow, Senior Researcher

**Reviewer's Country/Territory:** Egypt

**Author's Country/Territory:** China

**Manuscript submission date:** 2021-09-19

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-09-20 07:59

**Reviewer performed review:** 2021-09-20 08:49

**Review time:** 1 Hour

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="radio"/> ] Anonymous [ <input type="radio"/> ] Onymous Conflicts-of-Interest: [ <input type="radio"/> ] Yes [ <input checked="" type="radio"/> ] No
-------------------------------------	---

## SPECIFIC COMMENTS TO AUTHORS

First of all, I'd like to thank the publisher and the authors for giving me the privilege of this review. I also congratulate the authors for presenting such a rare case of hepatoid gastric adenocarcinoma

- 1-In the abstract; Mention, what were the complications that the patient died of?
- 2-Why there was no trial of palliative resection, no notification about the patient general, nutritional status and fitness for anesthesia?
- 3-Why the other treatment modalities were not tried, e.g palliative gastrectomy.
- 4-Do you have any role for MDT / tumor board discussion for organization of the proper plan for patient condition.
- 5-How about the patient nutritional status with such a big proximal gastric cancer , any role for feeding jejunostomy or naso-jejunal feeding tube or TPN?
- 6-The patient died of intestinal infection is not understood , what do you mean by this , which type of infection, when & where he was hospitalized, how did you guarantee that this was not a side effect of CTH?
- 7-Why you didn't mention, how many cases were recorded in literature??

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 71711

**Title:** Treatment of gastric hepatoid adenocarcinoma with pembrolizumab and bevacizumab combination chemotherapy: A case report

**Provenance and peer review:** Unsolicited manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05212440

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Academic Research, Associate Professor

**Reviewer's Country/Territory:** Saudi Arabia

**Author's Country/Territory:** China

**Manuscript submission date:** 2021-09-19

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-09-19 15:07

**Reviewer performed review:** 2021-09-26 18:33

**Review time:** 7 Days and 3 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="checkbox"/> ] Anonymous [ <input type="checkbox"/> ] Onymous Conflicts-of-Interest: [ <input type="checkbox"/> ] Yes [ <input checked="" type="checkbox"/> ] No
-------------------------------------	---

## SPECIFIC COMMENTS TO AUTHORS

Abstract: - Add detailed data about the participants (diagnosis, BMI, recruitment, settings). - Results without p-values do not provide noteworthy findings. - The conclusion should be precise. Add the future directions. Introduction: - This section cannot cover all the elements of the study. - Define "Gastric hepatoid adenocarcinoma" in detail. - Explain the measured variables. - The significance of the study needs more details. Methods: - The study design, ethics, and setting are not clear. - How and who administrates the data collection? - How did you achieve the validity and reliability of the outcome measures? - For statistical analysis, explain all methods used in detail and add the software used. - Please, re-frame the components (SPICES) for methods i. Study design, setting ii. Participant iii. Intervention/issue of interest (exposure) iv. Comparison v. Ethics and endpoint vi. Statistical analysis - What were the eligibility criteria? - Mention the settings and locations where the data were collected. - Provide sufficient details of the intervention. Results: - Results need to provide answers to the questions raised/researchable problem - Results need to follow ABC (accuracy, brevity, clarity) - Kindly frame it along with the following elements of results i. Text to tell the story ii. Tables to summarize the evidence iii. Figures to highlight the main findings - Kindly provide dates defining the periods of recruitment and follow-up. - This section needs to be put in the line with objectives. - Explain Recruitment and Baseline data. - Outcomes and estimation need to be explained well. Discussion - Add an introductory paragraph to explain the main findings based on the objectives and hypothesis of the study. - Compare the findings with previous studies. - Explain strengths and limitations in detail. - Add your recommendations and future directions. Conclusion: - Add your

"brief message" for the readers and researchers.

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 71711

**Title:** Treatment of gastric hepatoid adenocarcinoma with pembrolizumab and bevacizumab combination chemotherapy: A case report

**Provenance and peer review:** Unsolicited manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 03117998

**Position:** Editorial Board

**Academic degree:** MBBS, MD

**Professional title:** Professor

**Reviewer's Country/Territory:** India

**Author's Country/Territory:** China

**Manuscript submission date:** 2021-09-19

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2021-09-23 16:55

**Reviewer performed review:** 2021-09-30 16:55

**Review time:** 6 Days and 23 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="checkbox"/> ] Anonymous [ <input type="checkbox"/> ] Onymous Conflicts-of-Interest: [ <input type="checkbox"/> ] Yes [ <input checked="" type="checkbox"/> ] No
-------------------------------------	---

#### **SPECIFIC COMMENTS TO AUTHORS**

There are too many figures for a case report, please limit the figures to 2 or 3 (you can combine the figures as 1A, 1B, 1C etc) The case report highlights the potential treatment option for a rare type of liver cancer and resulted in the better prognosis, however the treatment proposed may not fit for all patients with GHA and needs further evaluation in a larger cohort or a randomized controlled trial.